tyrosine kinase inhibitor Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (2)

Phase 1/2 (1)
Unknown (1)

Interventional (1)
Observational (1)

Huiqiang Huang (1)
The First Affiliated Hospital of Zhengzhou University (1)

No (2)

No (2)

Adult (18+) (2)

I am/have/had

I am/have/hadpulse oximetry

I am/have/hadtubal ligation

I am/have/hadvascular endothelial growth factor receptor 2

I am/have/hadpositron emission tomography

I am/have/haddifficulty breathing at rest

I am/have/hadblood transfusion

I am/have/haddiffuse large b-cell lymphoma

I am/have/hadlymphoma

I am/have/hadmeasurable disease

I am/have/hadtyrosine

I am/have/hadprothrombin time (pt)

I am/have/hadb-cell lymphoma

I am/have/hadserum bilirubin

I am/have/hadct scan

I am/have/hadliver metastasis

I am/have/hadglioma

I am/have/hadmetastasis

I am/have/hadthyroid dysfunction

I am/have/hadebv-positive dlbcl, nos

I am/have/hadimmunodeficiency

added new label for I am/have/had

more

I am looking for

I am looking for18f-fdg

I am looking forgranulocyte colony stimulating factor

I am looking forcamrelizumab

I am looking fortyrosine

I am looking forcolony stimulating factor

I am looking forvegf

I am looking forgrowth factor

I am looking forrituximab

I am looking forvascular endothelial growth factor

I am looking forapatinib

I am looking foranticoagulants

I am looking forg-csf

I am looking fororal contraceptives

added new label for I am looking for

more

Advanced Filters

Loading...

Found 2 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

This study will evaluate the efficacy and safety of camrelizumab in combination with apatinib in in patients with relapsed or refractory diffuse large B cell lymphoma failed from second line chemotherapy.

18f-fdg

pulse oximetry

tubal ligation

positron emission tomography

diffuse large b-cell lymphoma

0 views
19 Feb, 2024

Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas

Apatinib, also known as YN968D1, is a small-molecule tyrosine kinase inhibitor (TKI) that selectively binds to and inhibits vascular endothelial growth factor receptor 2 (VEGFR-2). This study aims to collect clinical, radiological and histopathology imaging including detailed radiological data, survival data, clinical parameters, molecular pathology and images of HE slices …

tyrosine

hypertension

vegf

vascular endothelial growth factor receptor 2

postoperative complication

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2025 All rights reserved.